Symbiotec Pharmalab Ltd. IPO

Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company serves domestic and international markets across regulated and emerging regions.

With over 30 years of industry experience, Symbiotec Pharmalab has evolved from a lab-scale steroidal hormone API manufacturer in 1995 into an industrial-scale, backward-integrated manufacturing platform. The company has approvals from the United States Food and Drug Administration (US FDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea, and other global regulatory organisations.

As of June 30, 2025, the company operated two industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and fermentation capacity of 300 kilolitres.

Symbiotec Pharmalab focuses on research-driven manufacturing, quality compliance, and sustainable production processes. It supports the pharmaceutical, nutraceutical, and wellness industries by providing high-quality ingredients aligned with global standards.

Competitive Strengths:

  • Global leadership in corticosteroid and steroidal hormone APIs.
  • Long-standing relationships with domestic and international customers.
  • Fully invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and a strong regulatory track record.
  • Continuous investment in research and development, supported by strong technological capabilities among Indian industry peers.
  • Ability to leverage its scientific expertise and existing capabilities to expand its total addressable market and develop intellectual property-driven offerings.

Company Financials (Restated)

Symbiotec Pharmalab Ltd.’s revenue increased by 15% and profit after tax (PAT) rose by 14% between the financial year ending with March 31, 2026 and March 31, 2025.

Period Ended31 Mar 202631 Mar 202531 Mar 2024
Assets1,780.791,579.651,294.79
Total Income872.26755.98723.33
Profit After Tax109.9096.79100.06
EBITDA231.97206.11177.04
NET Worth1,158.64821.15720.68
Reserves and Surplus1,145.95810.03709.54
Total Borrowing387.91540.92247.21
Amount in ₹ Crore

Recently Listed IPOs in Pharmaceuticals

CompanyIssue TypeIssue SizeIssue PricePE RatioListing Day CloseListing Gain/Loss %LTP
Hexagon Nutrition Ltd.Mainboard₹138.87 Cr₹4522.69₹53.19+18.20%₹70.21
Sai Parenteral’s Ltd.Mainboard₹408.79 Cr₹39272.19₹405.70+3.49%₹540.85
Corona Remedies Ltd.Mainboard₹655.37 Cr₹106243.47₹1,438.40+35.44%₹2,142.60
 

IPO Objects of the Issue

The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:

#Issue ObjectsEst Amt (₹ Cr.)
1Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company112.50
2General corporate purposes 

Key Performance Indicator (KPI)

KPIMar 31, 2026Mar 31, 2025
ROE11.19%12.66%
ROCE11.56%11.80%
RoNW9.48%11.79%
PAT Margin12.60%12.80%
EBITDA Margin26.59%27.26%
NAV184.69150.17
Price to Book Value5.356.58

IPO Valuation

Valuation MetricPre IPOPost IPO
EPS (₹)17.8217.39
P/E (x)55.4456.81

Symbiotec Pharmalab IPO Details

IPO Date 24 to 27 Aug, 2026
Listing Date Tue, Sep 1, 2026T
Face Value ₹2 per share
Price Band ₹938 to ₹988
Lot Size 15 Shares
Sale Type Fresh capital cum OFS
Issue Type Bookbuilding IPO
Listing At BSE, NSE
Employee Discount ₹90.00
Total Issue Size 1,77,86,442 shares (agg. up to ₹1,757 Cr)
Fresh Issue 15,21,261 shares (agg. up to ₹150 Cr)
Offer for Sale 1,62,65,181 shares of ₹2 (agg. up to ₹1,607 Cr)
Share Holding Pre Issue 6,16,81,496 shares
Share Holding Post Issue 6,32,02,757 shares

SHARIAH SCREENING for - Symbiotec Pharmalab Ltd. IPO

BUSINESS SCREEN

FINANCIAL RATIOS

As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in

Spread the Knowledge - Share the Latest IPO Updates and Shariah Compliant IPO's.

Latest Current & Upcoming IPOs in BSE & NSE - Including Shariah Compliant.

The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.

IPO

Madhur Knit Crafts IPO Details

Last Updated on August 24, 2026 Madhur Knit Crafts Ltd. IPO Incorporated in August 1997, Madhur Knit Crafts Limited is a textile manufacturing company engaged in the production of fabrics,

Read More »
IPO

ABH Healthcare IPO Details

Last Updated on August 24, 2026 ABH Healthcare Ltd. IPO Incorporated in 2021, ABH Healthcare Ltd provides healthcare services, operates under the name “Anil Baghi Hospital”. The company has 150

Read More »
IPO

Symbiotec Pharmalab IPO Details

Last Updated on August 24, 2026 Symbiotec Pharmalab Ltd. IPO Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company engaged in the development and manufacturing of active

Read More »

Dear Halal Stock Users,

If you believe our website is a valuable resource,
we invite you to support us.
Your contribution ensures free access for all
and fuels future development.

You can contribute as little as
100, 200, 500 & so…
every bit counts.

Thank you for your support!